Cancer treatment has long been a complex challenge, but precision oncology has transformed the field by driving the development of targeted therapies and refining existing approaches. At the heart of this revolution are molecular biomarkers, essential tools for identifying patients who will benefit most from personalized treatments. Biomarkers have vast potential in oncology, aiding in risk assessment, screening, prognosis, diagnosis, treatment response prediction, and disease monitoring. Several biomarkers are already integral to clinical practice. As biomarker research accelerates, it is critical to search for markers with greater sensitivity, specificity, and predictive power. These advancements improve diagnostic accuracy and therapeutic outcomes, ultimately enhancing cancer care and patient survival.

About the Speaker

Dr. Afsheen Raza is a distinguished researcher and academician with twenty years of experience and a prolific track record of high-impact publications. She has worked in cancer research for over 15 years and has led major preclinical and clinical studies across a large spectrum of cancers.

Dr. Afsheen has published extensively on cancer biomarkers and is one of the leading researchers in this specialized area in the MENA region. As Director of Abu Dhabi University Cancer Research Institute (ADU-CRI), she is responsible for leading high impact research in precision and personalized cancer medicine to improve and advance patients care and outcomes in the UAE and beyond. She is also an Associate Professor of Molecular Biology and teaches Genetics, Immunology, and Cancer Biology.